Allopregnanolone in Chronic Complex Traumatic Brain Injury
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study will determine if allopregnanolone (ALLO) improves depression and pain symptoms in
patients who have a history of mild traumatic brain injury (TBI) [primary endpoints]. The
investigators will also determine if ALLO improves functional outcome [secondary endpoint].
Participants in this study will receive an intravenous infusion of either ALLO or placebo.
Behavioral assessments will be conducted during the infusion and at several time points
post-infusion.